Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
CBMG's Cash-to-Debt is ranked higher than
87% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. CBMG: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CBMG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.93
CBMG's Equity-to-Asset is ranked higher than
93% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CBMG: 0.93 )
Ranked among companies with meaningful Equity-to-Asset only.
CBMG' s Equity-to-Asset Range Over the Past 10 Years
Min: -279.5  Med: 0.89 Max: 0.97
Current: 0.93
-279.5
0.97
Interest Coverage No Debt
CBMG's Interest Coverage is ranked higher than
83% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBMG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CBMG' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 18.74
Beneish M-Score: 2.93
WACC vs ROIC
22.35%
-92.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -8106.75
CBMG's Operating Margin % is ranked lower than
92% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. CBMG: -8106.75 )
Ranked among companies with meaningful Operating Margin % only.
CBMG' s Operating Margin % Range Over the Past 10 Years
Min: -24440  Med: -2391.7 Max: -126.02
Current: -8106.75
-24440
-126.02
Net Margin % -7579.14
CBMG's Net Margin % is ranked lower than
92% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. CBMG: -7579.14 )
Ranked among companies with meaningful Net Margin % only.
CBMG' s Net Margin % Range Over the Past 10 Years
Min: -24660  Med: -2347.1 Max: -122.17
Current: -7579.14
-24660
-122.17
ROE % -40.77
CBMG's ROE % is ranked lower than
52% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. CBMG: -40.77 )
Ranked among companies with meaningful ROE % only.
CBMG' s ROE % Range Over the Past 10 Years
Min: -245.45  Med: -56.74 Max: -40.77
Current: -40.77
-245.45
-40.77
ROA % -38.79
CBMG's ROA % is ranked lower than
57% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. CBMG: -38.79 )
Ranked among companies with meaningful ROA % only.
CBMG' s ROA % Range Over the Past 10 Years
Min: -617.21  Med: -84.85 Max: -38.79
Current: -38.79
-617.21
-38.79
ROC (Joel Greenblatt) % -443.81
CBMG's ROC (Joel Greenblatt) % is ranked lower than
56% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. CBMG: -443.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CBMG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1084.27  Med: -1029.83 Max: -443.81
Current: -443.81
-1084.27
-443.81
3-Year Revenue Growth Rate 9.50
CBMG's 3-Year Revenue Growth Rate is ranked higher than
60% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CBMG: 9.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CBMG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 20.65 Max: 81.7
Current: 9.5
0
81.7
3-Year EBITDA Growth Rate 1.70
CBMG's 3-Year EBITDA Growth Rate is ranked higher than
50% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CBMG: 1.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CBMG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -10.7 Max: 76
Current: 1.7
0
76
3-Year EPS without NRI Growth Rate 2.20
CBMG's 3-Year EPS without NRI Growth Rate is ranked higher than
54% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. CBMG: 2.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CBMG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.2 Max: 379.5
Current: 2.2
0
379.5
GuruFocus has detected 4 Warning Signs with Cellular Biomedicine Group Inc CBMG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CBMG's 30-Y Financials

Financials (Next Earnings Date: 2018-03-14)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CBMG Guru Trades in

CBMG Guru Trades in

CBMG Guru Trades in

Q2 2015

CBMG Guru Trades in Q2 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CBMG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325413    SIC: 2835
Compare:NAS:KALV, TSX:IMV, XKRX:060590, TSX:VBV, LSE:MTFB, NAS:CASI, AMEX:AST, NAS:FWP, NAS:ADVM, XPAR:ABVX, NAS:ALPN, XKRX:064550, NAS:ADXS, OSL:BGBIO, XKRX:217730, NAS:CDTX, ROCO:4152, LSE:TRX, NAS:ZYNE, NAS:OMED » details
Traded in other countries:1LX.Germany,
Headquarter Location:USA
Cellular Biomedicine Group Inc is a part of the healthcare sector. It is engaged in the development of new treatments for cancerous and degenerative diseases.

Cellular Biomedicine Group is a biotechnology company focused on the development of proprietary cell therapies for the treatment of cancer and degenerative diseases. The company has two major cell platforms: immune cell therapy for treating a broad range of cancers using cancer vaccines, Chimeric Antigen Receptor T-cell technologies, and anti-PD-1 technologies; and human-adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases. The immuno-oncology and stem cell research team is based in both China and the United States.

Top Ranked Articles about Cellular Biomedicine Group Inc

Cellular Biomedicine Group Opens its New Shanghai GMP Facility and Joint Laboratory
Thermo Fisher Scientific and Cellular Biomedicine Group Announce Strategic Partnership to Develop Manufacturing Processes
Cellular Biomedicine Group Executives to Present at Biotech and Money World HealthEx Forum in London
Cellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility
BioLife Solutions CryoStor® Cell Freeze Media Embedded in Cellular Biomedicine Group Clinical Trial of AlloJoin™
Cellular Biomedicine Group to Present at the Cantor Fitzgerald Global Healthcare Conference
Cellular Biomedicine Group (CBMG) Announces Stock Repurchase Program
Cellular Biomedicine Group (CBMG) Announces the Addition of a Second Clinical Site in the Expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I Clinical Trial for Its CARD-1 Trial in Patients with Non-Hodgkin Lymphoma (NHL)
Cellular Biomedicine Group Announces Results of 2017 Annual Meeting of Stockholders
Cellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell Therapies

Ratios

vs
industry
vs
history
PB Ratio 3.01
CBMG's PB Ratio is ranked higher than
67% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CBMG: 3.01 )
Ranked among companies with meaningful PB Ratio only.
CBMG' s PB Ratio Range Over the Past 10 Years
Min: 0.48  Med: 2.89 Max: 360
Current: 3.01
0.48
360
PS Ratio 484.11
CBMG's PS Ratio is ranked lower than
95% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. CBMG: 484.11 )
Ranked among companies with meaningful PS Ratio only.
CBMG' s PS Ratio Range Over the Past 10 Years
Min: 2.22  Med: 99.05 Max: 1222.22
Current: 484.11
2.22
1222.22
EV-to-EBIT -5.02
CBMG's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. CBMG: -5.02 )
Ranked among companies with meaningful EV-to-EBIT only.
CBMG' s EV-to-EBIT Range Over the Past 10 Years
Min: -867.8  Med: -6.8 Max: 100.2
Current: -5.02
-867.8
100.2
EV-to-EBITDA -5.61
CBMG's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. CBMG: -5.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBMG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -867.8  Med: -7 Max: 100.2
Current: -5.61
-867.8
100.2
EV-to-Revenue 407.73
CBMG's EV-to-Revenue is ranked lower than
91% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. CBMG: 407.73 )
Ranked among companies with meaningful EV-to-Revenue only.
CBMG' s EV-to-Revenue Range Over the Past 10 Years
Min: -281.8  Med: 118.7 Max: 1229.6
Current: 407.73
-281.8
1229.6
Current Ratio 4.94
CBMG's Current Ratio is ranked higher than
67% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CBMG: 4.94 )
Ranked among companies with meaningful Current Ratio only.
CBMG' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.83 Max: 23.51
Current: 4.94
0.01
23.51
Quick Ratio 4.94
CBMG's Quick Ratio is ranked higher than
68% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. CBMG: 4.94 )
Ranked among companies with meaningful Quick Ratio only.
CBMG' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.63 Max: 23.38
Current: 4.94
0.01
23.38
Days Inventory 267.04
CBMG's Days Inventory is ranked lower than
97% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. CBMG: 267.04 )
Ranked among companies with meaningful Days Inventory only.
CBMG' s Days Inventory Range Over the Past 10 Years
Min: 34.81  Med: 82.97 Max: 370.28
Current: 267.04
34.81
370.28
Days Sales Outstanding 162.35
CBMG's Days Sales Outstanding is ranked lower than
84% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. CBMG: 162.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBMG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.59  Med: 59.61 Max: 243.61
Current: 162.35
19.59
243.61
Days Payable 2.00
CBMG's Days Payable is ranked lower than
91% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. CBMG: 2.00 )
Ranked among companies with meaningful Days Payable only.
CBMG' s Days Payable Range Over the Past 10 Years
Min: 2  Med: 91.67 Max: 644.03
Current: 2
2
644.03

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -24.60
CBMG's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CBMG: -24.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBMG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -95.4  Med: -11.55 Max: -3.8
Current: -24.6
-95.4
-3.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 12.10
CBMG's Price-to-Net-Cash is ranked higher than
55% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. CBMG: 12.10 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CBMG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.73  Med: 11.31 Max: 42.84
Current: 12.1
1.73
42.84
Price-to-Net-Current-Asset-Value 9.86
CBMG's Price-to-Net-Current-Asset-Value is ranked higher than
56% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. CBMG: 9.86 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CBMG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.63  Med: 10.7 Max: 320.5
Current: 9.86
1.63
320.5
Price-to-Tangible-Book 5.12
CBMG's Price-to-Tangible-Book is ranked higher than
56% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. CBMG: 5.12 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CBMG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.17  Med: 5.09 Max: 300
Current: 5.12
1.17
300
Price-to-Median-PS-Value 4.89
CBMG's Price-to-Median-PS-Value is ranked lower than
96% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CBMG: 4.89 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CBMG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.06  Med: 0.99 Max: 7.02
Current: 4.89
0.06
7.02
Earnings Yield (Greenblatt) % -19.87
CBMG's Earnings Yield (Greenblatt) % is ranked lower than
76% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. CBMG: -19.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CBMG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -80  Med: -12.1 Max: 3.6
Current: -19.87
-80
3.6

More Statistics

Revenue (TTM) (Mil) $0.33
EPS (TTM) $ -1.71
Beta3.33
Short Percentage of Float2.06%
52-Week Range $5.05 - 15.00
Shares Outstanding (Mil)14.01

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 0 25
EPS ($) -1.56 -1.54 -1.72 -1.03
EPS without NRI ($) -1.56 -1.54 -1.72 -1.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}